MDXG
MiMedx Group, Inc. Healthcare - Biotechnology Investor Relations →
MiMedx Group, Inc. (MDXG) closed at $3.67 as of 2026-06-19, trading 40.8% below its 200-week moving average of $6.19. This places MDXG in the extreme value zone. The stock moved further from the line this week, up from -41.9% last week. The 14-week RSI sits at 32, indicating neutral momentum.
Trading volume is running at 1.0x of its 14-week average, which is in the normal range. The balance between buying and selling volume (1.11 ratio) is neutral — neither side is clearly dominating.
Over the past 909 weeks of data, MDXG has crossed below its 200-week moving average 15 times. On average, these episodes lasted 30 weeks. Historically, investors who bought MDXG at the start of these episodes saw an average one-year return of +4.1%.
With a market cap of $547 million, MDXG is a small-cap stock. The company generates a free cash flow yield of 11.1%, which is notably high. Return on equity stands at 13.8%. The stock trades at 2.1x book value.
Share count has increased 30.2% over three years, indicating dilution. This stock also meets the Yartseva multibagger criteria as a small-cap with strong free cash flow yield and reasonable book value.
Over the past 17.5 years, a hypothetical investment of $100 in MDXG would have grown to $204, compared to $1236 for the S&P 500. MDXG has returned 4.2% annualized vs 15.5% for the index, underperforming the broader market over this period.
Free cash flow has been volatile over the past several years, making the quality of earnings harder to assess.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: MDXG vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After MDXG Crosses Below the Line?
Across 15 historical episodes, buying MDXG when it crossed below its 200-week moving average produced an average return of +4.0% after 12 months (median -9.0%), compared to +15.6% for the S&P 500 over the same periods. 43% of those episodes were profitable after one year. After 24 months, the average return was -17.7% vs +31.3% for the index.
Each line shows $100 invested at the moment MDXG crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Bean Score Experimental
The Bean Score measures how far a stock's free cash flow yield has deviated from its own quarterly baseline, normalized by the stock's historical behavior. Between earnings dates, FCF is constant — so the score is purely a function of stock price. The levels below show at what prices MDXG would reach each dislocation threshold.
Dislocation Price Levels
Prices where MDXG's Bean Score would hit each σ threshold. Valid until next earnings report: 2026-07-29.
| Level | σ | Price | Signal |
|---|---|---|---|
| Deep Value | +2σ | $2.79 | Unusually cheap — potential buy zone |
| Value | +1σ | $3.04 | Cheap vs. own history |
| Fair Value | +0σ | $3.35 | Historical mean behavior |
| Expensive | -1σ | $3.73 | Expensive vs. own history |
| Deep Expensive | -2σ | $4.20 | Unusually expensive — potential trim zone |
Quarterly FCF & Yield Trailing twelve-month free cash flow and yield at each quarter end
Signal Accuracy Collecting Data
The Bean Score system is accumulating weekly data to validate signal accuracy. After 13+ weeks of history, this section will display win rates and average returns for each σ threshold crossing — answering the question: "When this score says cheap or expensive, does the price subsequently move in the expected direction?"
Theoretical framework — not backtested or forward-tested. The Bean Score uses trailing twelve-month free cash flow yield as a dislocation identifier. It measures whether the market has pushed a stock's yield unusually far from its own baseline behavior. These levels are reference points for identifying potential swing trade opportunities, not buy/sell signals. FCF values update quarterly with earnings; between reports, all movement is price-driven.
Dislocation Scores Experimental
Each score measures deviation from MDXG's own historical baseline — the same idea as the Bean Score, applied to different fundamentals. Positive means cheaper or more dislocated than this stock's norm. Scores marked σ are normalized by the stock's own variability; pp values are simple deltas from its recent baseline.
Theoretical framework — not backtested. These scores describe how unusual today's readings are for this specific company. They are starting points for research, not buy or sell signals. Annual-statement scores (buyback, accruals, FCF vs history) rest on only ~4 yearly data points and are deltas, not sigmas.
Historical Touches
MDXG has crossed below its 200-week MA 15 times with an average 1-year return of +4.1% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Jan 2009 | Jun 2012 | 176 | 90.3% | -58.8% | +46.8% |
| May 2016 | May 2016 | 3 | 5.5% | +98.7% | -48.2% |
| Aug 2016 | Sep 2016 | 3 | 3.6% | +126.3% | -49.7% |
| Jan 2017 | Feb 2017 | 1 | 3.1% | +107.1% | -52.9% |
| Feb 2017 | Feb 2017 | 1 | 1.4% | -1.8% | -54.0% |
| Feb 2018 | Dec 2020 | 147 | 87.7% | -59.8% | -53.1% |
| Sep 2021 | Oct 2021 | 4 | 12.1% | -47.0% | -40.3% |
| Dec 2021 | Jun 2023 | 77 | 54.8% | -54.0% | -39.2% |
| Oct 2023 | Nov 2023 | 4 | 5.2% | -4.3% | -39.6% |
| Apr 2024 | Apr 2024 | 3 | 5.1% | +6.2% | -43.0% |
| Jul 2024 | Aug 2024 | 3 | 6.4% | +10.8% | -43.2% |
| Sep 2024 | Oct 2024 | 8 | 14.6% | +16.1% | -40.3% |
| Apr 2025 | May 2025 | 1 | 0.7% | -41.8% | -41.9% |
| Jun 2025 | Jun 2025 | 3 | 5.9% | -40.4% | -39.2% |
| Jan 2026 | Ongoing | 24+ | 44.8% | Ongoing | -39.8% |
| Average | 30 | — | +4.1% | — |
Frequently Asked Questions
Is MDXG below its 200-week moving average?
Yes. As of 2026-06-19, MiMedx Group, Inc. (MDXG) is trading 40.8% below its 200-week moving average of $6.19. The current price is $3.67.
What is MDXG's 200-week moving average price?
MiMedx Group, Inc.'s 200-week moving average is $6.19 as of 2026-06-19. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when MDXG drops below its 200-week moving average?
MDXG has crossed below its 200-week moving average 15 times in our data. On average, buying at that moment produced a one-year return of +4.1%. These dips have historically been decent entry points. These episodes lasted 30 weeks on average.
Is MDXG a good value right now?
Here's what our data says about MDXG as of 2026-06-19: The stock is below its 200-week moving average, which is the starting point for our analysis. The 14-week RSI is 32. Free cash flow yield is 11.1%. Return on equity is 13.8%. Price-to-book is 2.1x. This is not a buy or sell recommendation — always do your own research.
How does MDXG compare to the S&P 500?
Over the past 17.5 years, $100 invested in MDXG would have grown to $204, compared to $1236 for the S&P 500. That's 4.2% annualized vs 15.5% for the index. MDXG has underperformed the broader market over this period.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-06-19